Genmab: Start of Ofatumumab Phase III Head to Head Study in Follicular Lymphoma
Advertisement
Genmab A/S announced the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin’s lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.
Approximately 516 patients in this open-label study will be randomized to receive ofatumumab (1000 mg) or rituximab (375 mg/m2) by intravenous infusion for four weekly doses. Patients who have stable or responsive disease will then receive single infusions of ofatumumab or rituximab every two months for four additional doses for a total of eight doses over nine months. The primary endpoint of the study is progression free survival.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Aviation_medicine
Immatics wins 2012 TiE50 Award
Category:Taxonomic_lists_(genera,_taxonomic)
Immatics appoints Peter Chambré as Chairman

Could eating fruit more often keep depression at bay? - Aston University study found frequent fruit eaters had greater positive mental wellbeing
Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs
Intercell Receives Milestone Payment From Merck & Co. Inc - Milestone Payment Triggered By Initiation Of Phase II Clinical Trial of Investigational Vaccine to Prevent S. aureus Infection
